Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: NTLA intelliatx.com
Intellia Therapeutics is a clinical-stage biopharmaceutical company developing in vivo CRISPR gene editing therapies intended as one-time, potentially curative treatments for severe diseases. Its lead candidate, lonvoguran ziclumeran (lonvo-z), is designed to inactivate the KLKB1 gene to permanently lower kallikrein and bradykinin levels in hereditary angioedema (HAE). The FDA has accepted the lonvo-z BLA under Priority Review with a PDUFA date of March 10, 2027, and the company is preparing a U.S. commercial launch in the first quarter of 2027. Its second late-stage candidate, nexiguran ziclumeran (nex-z), is designed to inactivate the TTR gene in the liver to treat transthyretin (ATTR) amyloidosis. Nex-z is in the MAGNITUDE (ATTR-CM) and MAGNITUDE-2 (ATTRv-PN) Phase 3 trials, with Intellia leading development and commercialization in collaboration with Regeneron. The company currently earns revenue only from collaborations, chiefly with Regeneron. It funds operations from cash reserves and a term loan facility of up to $400 million with OrbiMed. Updated
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would…
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly…
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That’s according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of the Moonshots…
Investors have become quite familiar with the Magnificent Seven, the group of tech giants that reshaped markets with their dominance in AI, cloud computing, and digital ecosystems by driving unprecedented growth. Initially…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Wednesday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Asana, Charles Schwab, Estee Lauder, General Electric, GitLab, Home Depot, Match, Ovintiv, SoFi Technologies and United Airlines.
Wednesday's top analyst upgrades and downgrades included Amazon.com, Blackstone, Caesars Entertainment, Dollar Tree, DraftKings, GlobalFoundries, IBM, Lyft, Marathon Oil, McDonald's, Palo Alto Networks, Starbucks, Target, Toast and ZScaler.
Thursday’s top analyst upgrades and downgrades included AutoZone, CrowdStrike, Estee Lauder, Morgan Stanley, Nvidia and Western Digital.
Friday's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Accenture, Amgen, AutoZone, Azek, Boeing, Dollar General, Etsy, Fidelity National Information Services, FedEx, NexTier Oilfield Solutions, S&P Global, Unity Software and Warner Bros.…
Tuesday's top analyst upgrades and downgrades included Apple, Continental Resources, Bilibili, Eaton, Hershey, Meta Platforms, Nio, NOV, PayPal and Southern Company.
Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont and Salesforce.com.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Friday's top analyst upgrades and downgrades included Biogen, CME, Dropbox, DocuSign, Nvidia, Ping Identity, Signet Jewelers and Tilray.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate Therapeutics, Intellia, Ionis, Monster Beverage and more.
Intellia Therapeutics is a clinical-stage biopharmaceutical company developing in vivo CRISPR gene editing therapies intended as one-time, potentially curative treatments for severe diseases.
The Wall Street consensus 12-month price target for NTLA is $23.11. NTLA price prediction →
